It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Treatment Study for Patients with Prostate Cancer Undergoing Active Surveillance

Clinical Trial Title: 
A randomized study of enzalutamide in patients with localized prostate cancer undergoing active surveillance (ENACT).
Clinical Trial Protocol ID: 
16091209
Clinical Trial Investigator Name: 
Srinivas Vourganti, MD
Clinical Trial Protocol Description: 

This is a multicenter, randomized, open label exploratory study, conducted in the US and Canada, evaluating the efficacy and safety of enzalutamide for extension of time to prostate cancer progression (pathological or therapeutic) in patients with clinically localized, histologically proven prostate cancer that is categorized as low risk or intermediate risk and who are under active surveillance.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have histologically proven adenocarcinoma of the prostate diagnosed within 6 months of screening.
  • Have the ability to swallow study drugs and to comply with study requirements throughout the study.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Genitourinary Cancers
Contact Phone: 
(312) 942-5526
Contact Name: 
Pam Sroka, BS, MT(ASCP), BSN, RN, CCRC